In an observational study of Western participants attending a Shipibo ayahuasca healing programme, scores for psychological well‑being, happiness, spirituality and quality of life increased significantly and remained elevated up to 12 months post‑stay. Improvements were associated with greater decentering (r = 0.57) and subgroup analyses suggest the changes were attributable to the centre stay rather than the mere passage of time.
Promoting well-being is one of the main goals to improve health in the world. We examined the well-being and quality of life over the course of one year in a sample that participated in an Indigenous Shipibo healing program where traditional healers work in a series of ayahuasca ceremonies. We also explored the role of decentering as a mediator of psychological well-being. Participants who attended the program responded to an online survey that included a Psychological Well-Being Scale; Oxford Happiness Questionnaire; The World Health Organization Quality of Life Spirituality, Religiousness, and Personal Beliefs scale; the WHO Quality of Life-BREF scale; and Decentering scale. Baseline (T0) and postassessment (T1) were completed by 200 individuals. Of these, 101 completed the follow-up assessment at three months (T2), 91 at 6 months (T3), and 94 at 12 months follow-up (T4) after leaving the center. ANOVA test was performed in a representative subsample to control the passing of time two months before attending the program (T-1). Pearson’s test was performed to examine the relationship between psychological well-being and decentering during the period of T0 and T1. A significant increase was observed in all the scales at all time points (p≤ 0.01). The subgroup analysis performed in a representative subsample allowed us to infer that the significant differences in outcomes are due to the effect of their stay at the center and not the passing of time. We found a relationship between decentering and the improvement of psychological well-being (r= 0.57;p< 0.01). Our results suggest that the Indigenous Shipibo healing work with ayahuasca has value to improve long-term well-being and quality of life for Westerners.
Papers cited by this study that are also in Blossom
Barbosa, P., Strassman, R. J., da Silveira, D. X. et al. · Comprehensive Psychiatry (2016)
Bouso, J. C., González, D., Fondevila, S. et al. · PLOS ONE (2012)
Rodríguez-Fornells, A., Ribeiro, S., Sanches, R. F. et al. · European Neuropsychopharmacology (2015)
Callaway, J. C., Mckenna, D. J., Grob, C. S. et al. · Journal of Ethnopharmacology (1999)
Gonzalez and colleagues frame this study within growing international interest in promoting well-being as a core public‑health and clinical objective. They contrast two traditions in well‑being research—the eudaimonic model (focusing on personal growth, autonomy, purpose and related constructs) and the hedonic model (focusing on life satisfaction and positive affect)—and note that both are relevant for comprehensive measurement. The authors situate ayahuasca within the wider category of traditional medicine, review its botanical composition (Banisteriopsis caapi and Psychotria viridis), prior evidence of safety from long‑term ceremonial use and laboratory studies, and emerging clinical findings that ayahuasca can have rapid antidepressant effects. They also note the global spread of ayahuasca practices and attendant concerns about cultural appropriation, variable practitioner competence, and lack of regulation. This prospective observational study set out to evaluate whether participation in a series of Shipibo‑led ayahuasca ceremonies at the Temple of the Way of Light (Iquitos, Peru) is associated with changes in multiple dimensions of well‑being over one year. The primary outcome was psychological well‑being; secondary outcomes included subjective happiness, spiritual well‑being, quality of life, and decentering. The investigators additionally planned to explore whether changes in decentering were associated with, and potentially mediated, changes in psychological well‑being. The study is presented as complementary to randomised trials, aiming to examine outcomes in a naturalistic, traditional healing context.
The study used a prospective, longitudinal, observational design. Participants were Western adults who had booked a retreat (9, 12, or 30 days) at the Temple of the Way of Light between 2015 and 2017 and provided online informed consent; ethical approval was granted by the Autonomous University of Barcelona ethics committee. Screening followed the centre's usual criteria: participants had to be 18 or older and were excluded if they had certain psychiatric diagnoses (psychosis, mania, depersonalisation), were taking contraindicated medications (e.g. MAOIs, SSRIs), had cardiovascular conditions, chronic high blood pressure, or were pregnant. Additional inclusion for this analysis required absence of current depression, anxiety, posttraumatic stress or grief and adequate English comprehension. Assessments were administered online at multiple timepoints: an optional T-1 (two months before the retreat) for a subgroup; baseline T0 (15 days before the retreat); T1 (15 days after leaving the centre); and follow‑ups at 3 months (T2), 6 months (T3), and 12 months (T4). Only participants who completed both T0 and T1 were included in the primary analytic sample. Data were collected with LimeSurvey and stored securely. Several validated self‑report instruments were employed. Psychological Well‑Being was measured with the 42‑item PWBS (six subscales); subjective well‑being with the 29‑item Oxford Happiness Questionnaire; spiritual well‑being with the WHOQOL‑SRPB; quality of life with the WHOQOL‑BREF (physical, psychological, social domains were used); and decentering with the 11‑item EQ‑Decentering scale. Two ayahuasca brew samples collected during enrolment were analysed by LC‑MS to quantify DMT and ß‑carbolines; concentrations for the two samples are reported in the text. Statistical analysis was performed in SPSS. Descriptive statistics were used for baseline and setting variables. Changes from baseline to each follow‑up were tested with paired t‑tests or Wilcoxon tests as appropriate, with Bonferroni correction for multiple comparisons. Effect sizes were calculated as Cohen's d, and 95% confidence intervals for means were reported for the primary outcome. Pearson correlation coefficients examined the association between change in decentering and change in psychological well‑being. A pre‑planned subgroup analysis (n=42) that included T-1, T0 and T1 used repeated measures ANOVA to help distinguish effects of the retreat from routine temporal change.
Of 437 people assessed for eligibility, 200 participants completed both baseline (T0) and post‑retreat (T1) assessments and constituted the primary analytic sample. Attrition at subsequent follow‑ups was substantial: non‑response rates were 49.5% at T2, 54.5% at T3, and 53% at T4. The sample reported motivations of spiritual growth (66.7%) and personal development (32.4%); 65.5% were ayahuasca‑naïve prior to the retreat. Participants spent on average 14.93 days (SD 7.58, range 9–31) at the centre and took part in a mean of 6.21 ceremonies (SD 1.57, range 1–12). When asked about the most relevant factor in their well‑being change during the stay, 54% cited ayahuasca, 36% the Shipibo healers, with smaller proportions citing other factors. Primary outcome: Psychological Well‑Being Scale total scores increased significantly from baseline at all post‑retreat timepoints (T1–T4, p < 0.01). Effect sizes were large across assessments: T1 d = 0.89 (95% CI 0.72–1.04), T2 d = 0.91 (95% CI 0.67–1.11), T3 d = 1.12 (95% CI 0.89–1.35), and T4 d = 0.82 (95% CI 0.56–1.07). Self‑acceptance was the PWBS subscale showing the largest improvement. Secondary outcomes: Subjective well‑being (Oxford Happiness) improved significantly at all follow‑ups (p < 0.01) with effect sizes ranging from moderate to large (T1 d = 0.76, 95% CI 0.62–0.90; T3 d = 0.91, 95% CI 0.68–1.12). The WHOQOL‑SRPB total score also showed significant increases at all timepoints (p < 0.01), with large effect sizes at several assessments (T1 d = 0.96; T3 d = 1.05; T4 d = 0.90). WHOQOL‑BREF domains (physical health, psychological health, social relationships) improved after the retreat, with the psychological health domain showing the largest effects (T1 d = 0.96, 95% CI 0.81–1.10; T3 d = 0.94, 95% CI 0.75–1.13). Decentering increased significantly at T1 and remained elevated at T2–T4 (all p < 0.01), exhibiting large effect sizes (T1 d = 0.97, 95% CI 0.82–1.12; T4 d = 0.87, 95% CI 0.61–1.10). Correlation and subgroup analyses: Change in decentering from T0 to T1 correlated moderately with change in PWBS total score over the same interval (r = 0.53; p < 0.01). In the subgroup (n = 42) who completed T-1, T0 and T1, repeated measures ANOVA showed no significant changes between T-1 and T0 but significant improvements between T0 and T1 across multiple measures, supporting the view that changes were associated with the retreat rather than the mere passage of time. Selected ANOVA results include Oxford Happiness F(2,82) = 26.14, p < 0.001 (T1 vs T0 effect size 0.99); WHOQOL‑SRPB F(1.4,57.3) = 49.02, p < 0.001 (d = 1.29); Psychological Health F(1.7,71.3) = 18.30, p < 0.001 (d = 0.83); Social Relationships F(2,80) = 22.00, p < 0.001 (d = 0.79); Decentering F(1.4,56.6) = 29.90, p < 0.001 (d = 0.95). Ayahuasca composition and use: LC‑MS of two brew samples found DMT at 2 mg/ml in both samples, harmine ∼2 mg/ml in both, harmaline 0.37–0.65 mg/ml, and tetrahydroharmine 1–2 mg/ml; no other psychoactive compounds were detected. At 3‑month follow‑up (T2) 92.5% expressed willingness to continue ayahuasca use, but 64.9% had not used ayahuasca in the 12 months after leaving the centre. Participants expressed concerns about risks when using ayahuasca in their home countries (92% reported exposure to various risks), including legal issues (71.3%), uncertainty about brew composition (40.8%), inability to consult professionals for adverse effects (26%), and personal safety/ethical practice concerns (40.3%). The authors report persistent benefits and adverse effects in a table, but detailed adverse‑event data are not fully presented in the extracted text.
Gonzalez and colleagues interpret their findings as evidence that participation in a series of Shipibo‑led ayahuasca ceremonies in a retreat context was associated with sustained increases in psychological, subjective, spiritual well‑being and quality of life up to one year. They highlight that the subgroup analysis including a T-1 assessment supports the view that these changes are attributable to the retreat period rather than to simple temporal trends. The authors emphasise decentering as an important psychological mechanism: decentering increased with a large effect size and its change correlated moderately with improvements in psychological well‑being, consistent with prior studies suggesting decentering as a mediator of psychedelic‑related benefits. The discussion positions these results alongside observational research and ritual use literature that reports elevated well‑being in long‑term ayahuasca users, and contrasts ceremonial ayahuasca practice with non‑ritual psychedelic use. The authors note the potential contribution of ritual, healer practice and contextual factors—what some frameworks call performative efficacy or contextual healing—in driving outcomes; 36% of participants judged the Shipibo healers’ work to be the most relevant factor in their well‑being change. They also advance a hypothesis that the benefits may reflect an experiential learning process triggered by intense, contextually rich experiences that can generate lasting changes in self‑regulation and meaning‑making. Several limitations are acknowledged. The naturalistic, non‑controlled design prevents isolation of ayahuasca's pharmacological effects from other components of the intervention (ceremony, healer work, group and environmental factors). Absence of a placebo or active control group precludes causal attribution. The sample is self‑selected, financially able to attend a retreat, and motivated by spiritual or personal growth, limiting generalisability. Recruitment was voluntary and not all retreatants were enrolled, and outcomes rely on self‑report measures subject to social desirability bias. The authors also raise ethical and policy considerations around vegetalismo's international uptake and the need for regulation to reduce risks for both Indigenous communities and international participants. Finally, they call for further research into vegetalismo as a traditional medicine system and for studies that explore mechanisms, safety and appropriate regulation, while noting that their data may support recognition of ayahuasca as an herbal medicine used within traditional contexts.
In recent years, a growing interest in well-being, both in society in general as well as in mental health care, developed. This trend is reflected in the World Health Organizationdefinition of mental health as "a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity". Promoting well-being has become a principal goal for improving health in general among academics, health-care professionals, and policymakers alike. Although there is no consensus on the definition of well-being, clinical research on this concept is rooted in two complementary schools of thought. The eudaimonic model postulates a psychological well-being that is achieved through the development of the human being's potential. This is determined by the combination of six factors: autonomy, self-acceptance, environmental mastery, positive relations with others, purpose in life, and personal growth. Alternatively, the hedonistic model defines well-being as a subjective state based on the pleasure and enjoyment of life, determined through three factors: life satisfaction, the presence of positive affect, and the absence of negative affect. In other words, hedonic construct deals exclusively with affect, measuring whether people are "feeling good", but should be complemented with the eudaimonic construct that deals with personal-value fulfillment and meaningfulness, whether people are "doing well" or not. One of the strategies to promote comprehensive human welfare at the international level has been to develop a strategic plan 2014-2023 to foster the appropriate integration, regulation, and supervision of traditional medicine (TM). Traditional medicine is the sum total of the knowledge, skill, and practices based on the theories, beliefs, and experiences indigenous to different cultures-whether explicable or not-used in the maintenance of health, as well as in the prevention, diagnosis, improvement, or treatment of physical and mental illness. Herbal medicines constitute the main component of traditional medicine, which has been used for thousands of years. Quality standards, safety, and efficacy of the herbal products are needed to be considered herbal medicines. However, governments and consumers are interested in more than herbal medicines and are now beginning to consider traditional medicine practices and practitioners and whether they should be integrated into health service delivery. Ayahuasca is an herbal concoction used for ritual and healing purposes since pre-Columbian times. It is usually obtained by boiling the pounded stalks of the vine Banisteriopsis caapi (Spruce ex Griseb.) Morton and the leaves of the bush Psychotria viridis Ruiz & Pav.. B. caapi contains ß-carboline alkaloids such as harmine, tetrahydroharmine (THH), and harmaline, that are reversible inhibitors of monoamine oxidase A (MAO-A), while P. viridis is rich in the tryptamine hallucinogen dimethyltryptamine (DMT), an agonist of serotonin (5-HT)1A/2A/2C and sigma-1 receptors. Quantitative determination of other inorganic elements have displayed safe administration concentrations in 19 samples made from these plants collected from the União do Vegetal. Safety has been demonstrated by the long history of use, in observational studies on long-term users in ceremonial contexts, and in the laboratory. Moreover, open trials and randomized trials have shown the efficacy of ayahuasca as a rapid antidepressant. Observational studies show a higher level of well-being in long-term users of ayahuascaand lifestyle modifications. Today, interest in ayahuasca is a global phenomenon. Outside its native Amazonian habitat, ayahuasca has a presence in dozens of countries, including other parts of South America, North America, Europe, Australia, New Zealand, and some parts of Asia. This expansion has happened through three ways: religions that use ayahuasca as a sacrament; the psychonautic use of ayahuasca brew by Western people and neo-ayahuasqueros; and the cross-cultural vegetalismo or Indigenous-style ayahuasca healing ceremonies conducted in an often overtly commodified way for non-Indigenous clients both in the Amazon and abroad. In these traditions, aspiring ayahuasqueros go through an extended and difficult period of training involving demanding dietary and behavioral restrictions-although real mastery is acknowledged to take decades or a lifetime. However, the absence of international regulation of ayahuasca use poses a number of serious risks, both for Indigenous peoples and for the international community in general. On the one hand, Indigenous people see the desecration and cultural appropriation of their knowledge, symbols, stories, ceremonies, dances, and songs, and fear that their ancestral heritage will be changed or lost. On the other hand, Westerners who take ayahuasca have no guarantees about the composition of the ayahuasca, unwanted pharmacological interactions, exposure to unreliable information, and unqualified and unethical practitioners. Since these risks underlie all traditional medicines using herbal medicines, the World Health Organization has promoted international recognition of traditional medicine by regulating the products, practices, and practitioners. It has included-for the first time-diagnostic criteria based on traditional Chinese medicine in the 11th edition of the International Classification of Diseases (ICD-11). This effort has a reciprocal impact on the safety of doctors and patients, both in the countries of origin and in the countries that import medicinal practices and products. For example, acupuncture is covered by public and private insurances in different European countries by accredited professionals favoring the exercise of good practices among professionals and patients. Knowledge-based policies are crucial for the integration of traditional medicine into national health systems, and research should be prioritized and supported in order to generate knowledge. Randomized placebo-controlled clinical trials provide a high internal validity but low external validity. Therefore, clinical trials in the laboratory have to be combined with observational research to study how these medical systems are working in the real world.
This article presents the results of a longitudinal observational study evaluating various parameters related to the psychological, subjective, spiritual well-being, and quality of life of Western people attending retreats at the Temple of the Way of Light in Iquitos, Peru (Temple of the Way of Light, 2016). Ceremonies are run by five male and female Shipibo onanyabo (the plural form of the Shipibo term for an ayahuasca practitioner), supported by two Western facilitators. Although these ceremonies are rooted in the traditional Shipibo medical system, they have been adapted to working with Western participants. According to the Shipibo onanyabo, their work over the course of the series of ceremonies follows a coherent and structured progression, with the first ceremony being a diagnostic session. As the ceremony begins, the first icaro that they perform is meant to create a safety structure around the ceremonial space, with the intention of protecting the participants from energetic interferences from the outside environment and between participants. Following Dobkin de, icaro is the generic name given to the medicine songs used by the curanderos of the Peruvian Amazon Basin (for a deeper review regarding icaros, see. During the initial diagnostic session, the onanyabo aims to detect energetic blockages in the participants, "scanning" their bodies with the help of the icaro. The following ceremonies, according to the onanyabo, aim to cleanse and clear "dense energies" that participants may carry. Although the Shipibo does not necessarily make the same conceptual connections, Western facilitators often understand these dense energetic knots to correlate with psychosomatic and emotional imprints leftover from individual and transgenerational traumas, repressed emotions, or self-sabotaging unconscious views that are rooted in past difficult life episodes, particularly childhood experiences. However, diagnosis is also a continuous process throughout the cleansing and clearing process, reaching into and revealing deeper layers of energetic and spiritual ways of being. When "heavy energies" are uncovered, the onanyabo claim to use icaros to disconnect and dispel them within the individual's body, sending the "energies" back into the earth. By clearing dense energies from the past, participants become "unstuck" and often significantly transform their relationship with themselves, others, and the world in general. Once the cleansing and clearing have been done, a culminating last ceremony occurs. The onanyabo focuses on sealing in the "spiritual surgery" and aligning the body, mind, and spirit, together with the perceived energetic structure of each participant, protecting the energetic and physical body while illuminating the pathway forward. In addition to the icaros, the Shipibo also works with Nicotiana rustica, commonly known as Mapacho, Aztec, Brazilian, or strong tobacco, as an important plant ally in the ceremony. They occasionally blow smoke on the participants to transmit the icaros, cleanse heavy energies, and maintain protections. In addition, several plants and flowers in the form of steam baths and flower baths are used outside of the ceremonies in order to cleanse the energies that are being pulled out by the icaros. Several perfumes, such as agua florida or pusanga, are also used to help the person "blossom" and attract positivity into their lives. The present study investigated the long-term effects of ayahuasca in the well-being of participants from a holistic view. The primary outcome of this study was psychological well-being. Secondary variables were subjective well-being, spiritual well-being, quality of life, and decentering. We hypothesized that the psychological well-being would be improved after drinking ayahuasca in this traditional healing work context still maintained after a one-year follow-up. Second, we hypothesized that subjective well-being, spiritual well-being, quality of life, and decentering would also improve after drinking ayahuasca. Given that previous studies have shown that decentering is a psychological process underlying ayahuasca's effectsand that this psychological process mediates psychological well-being, we finally hypothesized that changes in psychological well-being after being at the center will be mediated by changes in decentering.
This study is part of a broader research project that aims to prospectively assess the long-term effects of ayahuasca on psychopathological symptoms in different subsamples with depression, anxiety, posttraumatic stress disorder, and grief. Grief data have been published in a previous study. In the present article, only the data for the subsample that have not been previously diagnosed with a mental disorder and do not suffer from any of those psychopathological symptoms have been included and analyzed. The study was approved by the Ethics Committee on Animal and Human Experimentation of the Autonomous University of Barcelona (UABCEEAH Barcelona, Spain) and was conducted in accordance with the Declaration of Helsinki. Participants signed an online informed consent and were not financially compensated for their participation.
Participant enrollment was carried out between 2015 and 2017. During 2018, the follow-up period of one year was concluded. Participants were invited to participate in the study through the Web site of the Temple of the Way of Light (Temple of the Way of Light, 2016) after having booked their stay at the center. This center offered retreats of 9, 12, or 30 days, where participants drank ayahuasca between 1 and 12 times in a ceremonial context under the guidance of Shipibo onanyabo. A total of 200 participants were eligible for the analysis. The screening process involved two stages. First, to be accepted by the center, individuals had to be 18 years or older. Moreover, people with previous clinical disorders (psychosis, depersonalization, and mania), people taking certain medications (i.e., MAOIs or SSRIs), subjects with a heart condition, those with chronic high blood pressure, and pregnant women were not accepted (Temple of the Way of Light, 2019). Second, participants must respond to a short online questionnaire including the following questions: 1) Please indicate the exact date when you will attend to the retreat; 2) Please mark "yes," "uncertain," or "no" to the following questions: Are you currently going through a period of (b.1) depression, (b.2) anxiety, (b.3) posttraumatic stress, or (b.4) grief related to the death of a loved one; 3) Have been diagnosed with a mental disorder in the past?, and 4) Can you understand with ease everything you read in the English language? Participants were included in the study if they were not currently experiencing depression, anxiety, posttraumatic stress, and grief symptoms related to the death of a loved one; if they have not been diagnosed with certain mental disorders in the past; and if they affirmed having adequate knowledge of the English language. Once participants were included in the study, assessments were done 15 days before attending the retreat (T0) and 15 days (T1), three months (T2), six months (T3), and 12 months (T4) after leaving the center. Only participants who responded baseline (T0) and postassessment (T1) were finally included in the analysis. Participants who signed informed consent more than two months before attending the center were invited to respond to an additional assessment two months before entering the center (T-1) in order to control for the effect of time on outcomes in a subgroup. All questionnaires were administered online using LimeSurvey (version 1.92.), which allowed for the collection and preservation of the data for confidentiality on a secure server that is accessible only to the researchers with a secure password.
Psychological Well-Being Scales (PWBS)) is a 42-item Likert-type scale (1 completely disagree, 6 completely agree), which measures psychological well-being through scales of Self-Acceptance, Positive Relationships, Autonomy, Environmental Mastery, Personal Growth, and Purpose in Life. Scores in each domain range from 6 to 42 where higher scores indicate greater levels of well-being. In the current study, the sum of the score ratings across the six dimensions was added including an overall PWBS measure (α 0.89), with higher scores reflecting higher PWBS.
Oxford Happiness Questionnairemeasures happiness or subjective well-being. A series of statements about happiness are given and the participants indicate their degree of agreement with each one. In psychometric terms, it consists of 29 items, and the participants assess the extent to which they form part of their experiences. It employs a Likert scale (1 I totally disagree, 6 I totally agree). Reliability for this scale was found to be 0.91.
WHO Quality of Life Spirituality, Religiousness, and Personal Beliefs (WHOQOL-SRPB BREF) (WHOQOL SRPB) is a 32-item Likert scale (1 not at all, 5 an extreme amount), covering quality-of-life aspects related to spirituality, religiousness, and personal beliefs. It is divided into eight scales: Spiritual Connection, Meaning and Purpose in Life, Experiences of Awe and Wonder, Wholeness and Integration, Spiritual Strength, Inner Peace, Hope and Optimism, and Faith. Each facet score is derived by averaging the score obtained from the responses to the four questions comprising that particular facet. The domain score is calculated by adding the scores of the facets. Cronbach's a for the SRPB facets has been found to be strong, ranging from 0.77 (meaning and purpose in life) to 0.95 (faith), whereas Cronbach's a for the complete WHOQOL-SRPB instrument is excellent (α 0.93).
WHO Quality of Life-BREF (WHOQOL-BREF) (WHOQOL Group, 1998) is a shorter version of the original WHOQOL-100. This questionnaire was designed to assess quality of life in four domains: Physical Health, Psychological Health, Social Relationships, and Environment. It comprised 24 items, scored on a 4-20 scale, with higher scores indicating a better quality of life. For the purpose of this study, only the first three scales were used. The scale has been shown to have adequate psychometric properties with Cronbach's coefficient α values ranging from 0.68 to 0.82 (61).
EQ-Decentering: this scale assesses decentering, defined as the ability to observe one's thoughts and feelings in a detached manner. This is an 11-item, selfreport measure of decentering. Items are rated on a 5-point Likert scale (1 never to 5 always). The original EQ showed a highreliability coefficient with Cronbach's α value of 0.90.
Two ayahuasca samples collected during the participants' enrollment were analyzed. The ayahuasca was prepared by boiling the stems of Banisteriopsis caapi (Spruce ex Griseb.) Morton, rich in harmine, tetrahydroharmine, and harmaline, combined with the leaves of Psychotria viridis Ruiz & Pav., rich in DMT. Analyses were carried out by Energy Control (energycontrol-international.org) using liquid chromatography-mass spectrometry (LC-MS). One ayahuasca sample contained 2 mg/ml DMT, 2 mg/ml of harmine, 0.37 mg/ml of harmaline, and 1 mg/ml of tetrahydroharmine. The other sample contained 2 mg/ml DMT, 2 mg/ml of harmine, 0.65 mg/ml of harmaline, and 2 mg/ml of tetrahydroharmine. No other psychoactive compounds were detected.
Baseline sample characteristics, setting variables, persistent adverse effects, benefits of ayahuasca over time, and risk's perception of the ayahuasca use in the participants' original countries were analyzed descriptively. Changes in primary and secondary outcome variables between each time point and baseline were tested using Student's paired two-sided T-test or the Wilcoxon-paired test, as appropriate. Bonferroni corrections were applied to correct for multiple comparisons. A 95% CI for the mean of the primary outcome at all-time point assessments was included to further clarify plausible values. Effect sizes were calculated using Cohen's d. Effect sizes were defined as large up to 0.8 (d > 0.8), medium (d > 0.5), and small (d ≤ 0.2)). Pearson's linear correlation coefficient was used to examine the relationship between Decentering (EQ-Decentering) and Psychological Well-Being Scale (PWBS). Correlation coefficients between 0.30 and 0.70 were considered moderate. Additional subgroup analysis was performed separately for patients who responded to T-1, T0, and T1 assessments. We used the chi-square test for categorical variables and Fisher-Snedecor for continuous variables to evaluate homogeneity between the group that completed the follow-up at T1 and a subgroup that completed an additional assessment at T-1. Subgroup analyses were conducted using repeated measures analysis of variance (ANOVAs) with post hoc Bonferroni correction in order to examine differences in primary and secondary outcomes between the periods of T-1 to T0 and T1 to T0. Effect sizes were calculated using Cohen's d. In this study, p values <0.05 were considered statistically significant. Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS for Windows, version 20).
Out of 437 participants who were assessed for eligibility, 90.8% of participants signed the informed consent form. However, 18.4% of participants were excluded because baseline assessment (T0) was not available, 36.7% were excluded because postassessment was not available (T1), and 2% expressed a desire to abandon the study. Finally, 200 participants were eligible for the analysis, having completed the baseline and postassessment. Overall, the rate of participants not responding to the assessment at T2 was 49.5%, at T3 was 54.5%, and 53% at T4 (Figure).
The demographic characteristics of participants are summarized in Table. The motivations for attending the retreat were spiritual growth (66.7%) and personal development (32.4%). None of the participants indicated a therapeutic motivation or recreational purpose, such as drug tourism. Of the overall sample, 65.5% had never used ayahuasca before. Of the remaining 34% of the sample (n 68), 9.5% drank ayahuasca less than 4 times, 13% between 4 and 10 times, and 11.5% more than 10 times.
Participants attended an average of 14.93 (SD 7.58) days at the center (range 9-31), where they participated in an average of 6.21 (SD 1.57) ayahuasca ceremonies (range 1-12). Of the 200 participants who responded at T0-T1, 54% perceived ayahuasca as the most relevant factor in the evolution of their well-being during their stay at the center, followed by the work of the Shipibo healers (36%), being with other guests (6%), the experience of being in the jungle (2.5%), and having attended other alternative activities, such as yoga classes (1.5%).
The results for outcome variables at all assessment points (T0, T1, T2, T3, and T4) are presented in Table. Psychological Well-Being Scales Total score was significantly increased from baseline to all point times follow-up assessment (T1, T2, T3, and T4: p < 0.01). Calculating effect sizes according to Cohen's method, we found a high effect size at all assessment points (T1 0.89, 95% CI 0.72-1.04; T2 0.91, 95% CI 0.67-1.11; T3 1.12, 95% CI 0.89-1.35; and T4 0.82, 95% CI 0.56-1.07). Subjective well-being also showed a significant improvement at all-point assessments (T1, T2, T3, and T4: p < 0.01), showing a moderate effect size at T1 0.76, 95% CI 0.62-0.90; T2 0.58, 95% CI 0.37-0.77; and T4 0.69; 95% CI 0.45-0.90. Unexpectedly, the effects size was higher at T3 0.91 95% CI 0.68-1.12. Similarly, the WHOQOL-SRPB showed a significant improvement on the total score for all assessments (T1, T2, T3, and T4: p < 0.01), showing a high effect size at T1 0.96, 95% CI 0.80-1.11; T3 1.05, 95% CI 0.83-1.725; and T4 0.90, 95% CI 0.67-1.11. The effect size at T2 was medium. T2 0.71, 95% CI 0.52-0.90. The WHOQOL-BREF questionnaire also showed significant improvements in physical health, psychological health, and social relationship scales after the retreat (T1: p < 0.01). The effect size was larger for the psychological health scale (T1 0.96, 95% CI 0.81-1.10; T2 0.70, 95% CI 0.49-0.88; T3 0.94, 95% CI 0.75-1.13; and T4 0.70, 95% CI 0.51-0.87). Finally, decentering significantly improved after the retreat (T1: p < 0.01) and at all follow-up assessments (T2, T3, and T4: p < 0.01). Decentering also showed a high-effect size at all-time point assessments (T1 0.97, 95% CI 0.82-1.12; T2 0.87, 95% CI 0.66-1.06; T3 0.87, 95% CI 0.63-1.09; and T4 0.87, 95% CI 0.61-1.10). The improvements achieved in the key variables after the retreat remained stable at 12 months, with no significant differences observed between T4 and T1, except in spiritual strength (T4-T1 -0.20 (0.57); p 0.001) (Supplementary Table). Persistent benefits and adverse effects derived from the ayahuasca experiences at the center are shown in Table.
The significant increase in decentering between T0 and T1 was found to be associated with the significant increase in the Psychological Well-Being Total Scale between T0 and T1 (r 0.53; p < 0.01).
Of the 200 participants who completed the baseline and postassessment (T0 and T1), a subgroup of 42 participants who completed an additional assessment two months prior to the retreat (T-1) were eligible for the subgroup analysis (ANOVA). The homogeneity of the groups was tested by comparing key variables (baseline characteristics, primary and secondary outcome measures). Significant differences were found only in people with a university degree (control subsample 87.3%; subsample 73.8%; p 0.031). No other significant differences were found in primary and secondary outcomes measures (p > 0.05). The average number of days registered in the subsample between T-1 and T0 was 44.29, and between T0 and T1, it was 46.0 (SD 9.13). Mean values of primary and Similarly, ANOVA revealed a significant main effect of time on secondary variables during participants' stays at the center (Figure). Oxford Happiness Questionnaire [F (2; 82) 26.14; p < 0.001] shows an improvement only between T1 and T0 [0.61 (SD 0.61); p < 0.001] and not between T0 and T-1 [-0.07 (SD 0.55); p > 0.999]. The effect size between T1 and T0 was large (0.99; 95% CI, 0.66-1.31). Total Scale of WHOQOL-SRPB [F (1.4; 57.3) 49.02; <0.001] shows the improvement only between T1 and T0 [0.58 (SD 0.45); p < 0.001] and not between T0 and T1 [-0.06 (SD 0.26); p 0.504). The effect size between T1 and T0 was large (1.29; 95% CI, 0.93-1.65). The subscales of the WHOQOL-BREF show a similar pattern, being Psychological Health Scale improved [F (1.7; 71.3) 18.30; p < 0.001; d 0.83; 95% CI, 0.53-1.13], only between T1 and T0 [1.31 (SD 1.58); p < 0.001] and not between T0 and T1 [0.12 (SD 1.48); p > 0.999], and Social Relationships Scale improved [F (2; 80) 22.00; p < 0.001; d 0.79; 95% CI, 0.44-1.15] only between T1 and T0 [1.76 (SD 2.22); p < 0.001] and not between T0 and T1 [0.37 (SD 1.80); p 0.574]. Finally, the significative increase in decentering [F (1.4; 56.6) 29.90; p < 0.001] is observed only between T1 and T0 [6.32 (SD 6.68); p < 0.001) and not between T0 and T1 [-0.78 (SD 3.32); p 4.111]. Effect size between T1 and T0 was large (0.95; 95% CI, 0.65-1.26).
At T2, 92.5% of the sample wished to continue taking ayahuasca in the future. However, only 14.9% drank ayahuasca between 1 and 3 times, 11.7% between 4 and 10 times, and 8.5% more than 10 times at T4. This means that 64.9% of the sample didn't drink ayahuasca over the 12 following months after leaving the center. Nevertheless, 92% of the sample affirmed to be exposed to several risks in taking ayahuasca in their country of origin, such as legal charges (71.3%), health problems due to the lack of guarantees regarding the composition of ayahuasca (40.8%), or the disability to consult with professional experts in case of adverse effects (26%). Moreover, 40.3% of the sample affirmed risks related to their personal safety not being able to guarantee that the person administering ayahuasca follows a professionally regulated practice and complies with a code of ethics. Finally, more than a half of the sample (59.7%) affirmed that ayahuasca should be practiced by Amazonian healers or practitioners with comprehensive traditional training.
In this prospective, observational non-controlled study, we examined the long-term impact that ayahuasca, used in a ceremonial Shipibo context, can have on the integral wellbeing of the individual. Participants who have completed the evaluations throughout the year show a significant increase in psychological well-being, subjective well-being, spiritual wellbeing, and quality of life after the stay in the retreat. These outcomes are confirmed by the reports of most of the participants who affirmed sustained benefits on personal well-being over one year, followed by spiritual benefits. The subgroup analysis performed in a representative subsample allowed us to infer that the significant differences in outcomes are due to the effect of their stay at the center and not the passing of time. Well-being is a relevant worldwide factor directly linked to the prevention of mental disorders as well as to the promotion of mental health. In fact, well-being is a highly complex construct that entails physical, mental, and social wellbeing. The results presented in this article show a significant and sustainable long-term improvement in well-being from a holistic view, including the physical and social relationships quality of life in addition to psychological, subjective, and spiritual well-being. These results are in line with several studies that have observed a high level of wellbeing in people who take ayahuasca regularly in ritual communitarian context, and in religious ceremonies. Ayahuasca users have shown even higher wellbeing than those who had taken classic psychedelics such as LSD or Psilocybe mushrooms, especially in life satisfaction, social relationships, spiritual awareness, and attitudes about self and life. Since LSD or mushrooms are not usually used in a ritual context, these results lead us to consider the role of the ceremony in the positive and long-term impact on the well-being of the Western people.argues that the alternative medicine used in ritual settings may administer an especially large dose of "performative efficacy," which relies on the power of belief, imagination, symbols, meaning, expectation, persuasion, and self-relationship. These factors could be understood in biomedical science as the placebo effect or whatcall "contextual healing." Indeed, in our sample, 36% of the participants affirmed that the work of the Shipibo healers was the most important factor in the improvement of their well-being, even more than ayahuasca itself. However, as it has been explained in the introduction, Shipibo healers claim to be performing a specific medical intervention that is not explicable by our Western, materialist worldview, probably because of our epistemological and perceptual biases. Expanded scienceis necessary to establish the extent to which the medical intervention of the healers could be conceived as performative contextual healing or whether it is a qualified and replicable medical practice rooted in indigenous knowledge and the underlying ontologies. The effect size is high in all PWBS total assessments, selfacceptance being the subscale which presents a higher improvement after the retreat and follow-up assessments. Selfacceptance is defined as a positive attitude toward oneself that entails a regulation process of the self-concept, which is one of the most significant and powerful regulators of behavior and affect. Distortions in the experience of one's "self" are central to the psychedelic experience, such as in the "ego-dissolution experiences". However, following, self is also a construct cocreated by culture, societies, and individuals at a particular time and place, which is constituted in relationship with others. This implies that beyond the phenomenological experience with ayahuasca, the reflection process of the experience during the integration sessions where people are able to share in a collective with their own subculture could allow for the organic emergence of new meanings about the self that could be easier to accept. Indeed, several authors describe how ayahuasca ceremonies may enhance interpersonal bonds and social identity (Dobkin de. Another ability related to self-regulation is decentering, which engenders disidentification from internal experiences and reduced reactivity to thought content. This is an important mechanism of change that functions as an emotional regulation-mediating process underlying different salutary effects. Given the relevance of this mechanism to promote health and well-being, multiple clinical intervention programs focus on teaching patients the techniques to develop this ability. Our results show a high-effect size in the ability of decentering at all point assessments as well as a moderate correlation between the improvement in decentering and psychological well-being after the retreat. These results are supported by several studies, which have found a significant improvement in this ability, 24 h after taking ayahuasca, being maintained over one-year follow-up. Given that the development of this skill has not been formally taught in the ayahuasca ceremonies of those previous studies, these results lead us to hypothesize about the possibility that the development of this ability could be acquired and sustained long-term through an experiential learning processwith what is traditionally known as "master plants". Experiential learning is an embodied, complex process often triggered by an emotionally intense experience in a contextually rich learning environment that becomes embodied in memory traces. Understanding the benefits of ayahuasca as an experiential learning process opens the door to investigating multiple mechanisms of action that have not yet been studied in depth in the field of psychedelics, such as the mediating role of cognitive reappraisal and contextualized meaning-making. It is important to consider the limitations of this study. First, the naturalistic design of the study does not allow us to isolate the effects of ayahuasca from the other diverse variables in the setting, which include the work of the Shipibo onanyabo during the ayahuasca ceremony. In fact, the separation of the effects of ayahuasca from the onanyabo's work is not conceived within this traditional medicine system. Moreover, without a placebo control group, it is not possible to determine the efficacy of ayahuasca as herbal medicine to promote well-being. Second, the sample selected is not representative of the general population as they must have financial resources to attend this center, and all of them wish to drink ayahuasca motivated by personal or spiritual growth at baseline. Third, since participation in the study was not mandatory for people who signed up for the retreats, not all those who attended the center during the two-year period were recruited for the study. Furthermore, social desirability response bias is associated with the use of self-report questionnaires. Vegetalismo, which includes the use of ayahuasca and many other plant medicines, is still the primary operational healthcare system in the Peruvian jungle since it is empirically efficient for the people, deeply rooted in the culture, and financially accessible. At the same time, more and more Western people travel to the Peruvian cities, such as Iquitos, in search of other alternative forms of healing and self-transformation they do not find in the Western biomedical system. However, in the absence of international regulation of this medical system, people are exposed to several risks; these risks were mentioned by 92% of the sample. Enhancing well-being is the best way to promote mental healthand the vision of the World Health Organization is the attainment of the highest possible level of health by all people (WHO, 2020a). In view of this, we hope that this study can contribute to the further recognition of ayahuasca as a herbal medicine used in the traditional medical context. Future studies are needed to explore and evaluate vegetalismo as a traditional medicine system.
Create a free account to open full-text PDFs.
Domínguez-Clavé, E., Soler, J., Pascual, J. C. et al. · Psychopharmacology (2018)
Fábregas, J. M., González, D., Fondevila, S. et al. · Drug and Alcohol Dependence (2010)
Franquesa, A., Sainz-Cort, A., Gandy, S. et al. · Psychiatry Research (2018)
Griffiths, R. R., Hurwitz, E. S., Davis, A. K. et al. · PLOS ONE (2019)
Halpern, J. H., Sherwood, A. R., Passie, T. et al. · Medical Science Monitor (2008)
Jiménez-Garrido, D. F., Gómez-Sousa, M., Ona, G. et al. · Scientific Reports (2020)
Lawn, W., Hallak, J. E., Crippa, J. A. et al. · Scientific Reports (2017)
Mello, S. M., Soubhia, P. C., Silveira, G. et al. · Journal of Psychoactive Drugs (2018)
Murphy-Beiner, A., Soar, K. · Psychopharmacology (2020)
Nour, M. R., Evans, J., Nutt, D. J. et al. · Frontiers in Human Neuroscience (2016)
Ona, G., Kohek, M., Massaguer, T. et al. · Journal of Psychoactive Drugs (2019)
Osório, F. L., Sanches, R. F., Macedo, L. et al. · brazilian Journal of Psychiatry (2015)
Palhano-Fontes, F., Barreto, D., Onias, H. et al. · Psychological Medicine (2018)
Riba, J., Valle, M., Urbano, G. et al. · Journal of Pharmacology and Experimental Therapeutics (2003)
Sanches, R. F., Osório, F. L., Dos Santos, R. G. et al. · Journal of Clinical Psychopharmacology (2016)
Soler, J., Elices, M., Franquesa, A. et al. · Psychopharmacology (2015)
Papers in Blossom that reference this study
Bouso, J. C., Andión, Ó., Cantillo, J. et al. · Psychedelics (2026)
Bonomo, Y. A., Norman, A. F., Collins, L. et al. · Frontiers in Psychiatry (2025)
Turkia, M. · Psyarxiv (2023)
Turkia, M. · Psychiatry Research (2022)
Bouso, J. C., Andión, O., Sarris, J. et al. · PLOS Global Public Health (2022)
Perkins, D., Pagni, B. A., Sarris, J. et al. · Frontiers in Pharmacology (2022)
Pontual, A. A. D. D., Tófoli, L. F., Corradi-Webster, C. M. et al. · Frontiers in Psychology (2022)
Ruffell, S. G. D., Gandy, S., Tsang, W. et al. · Psyarxiv (2022)
Kohek, M., Ona, G., Dos Santos, R. G. et al. · Journal of Psychoactive Drugs (2022)
Madrid-Gambin, F., Gomez-Gomez, A., Busquets-Garcia, A. et al. · Biomedicine & Pharmacotherapy (2022)
Ruffell, S. G. D., Netzband, N., Tsang, W. et al. · Frontiers in Psychiatry (2021)